• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Adicet Bio Inc.

    6/5/24 5:19:41 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ACET alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001364719
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Adicet Bio, Inc.
    SEC File Number
    001-38359
    Address of Issuer
    131 Dartmouth Street, Floor 3
    BOSTON
    MASSACHUSETTS
    02116
    Phone
    617-482-2333
    Name of Person for Whose Account the Securities are To Be Sold
    Kauffman Michael
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    COMMON
    Morgan Stanley Smith Barney LLC Executive Services
    200 W Civic Center Dr - 4th Floor
    SANDY � UT � 84070
    59008437.008220000006/05/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    COMMON06/01/2024RESTRICTED STOCKISSUERCheckbox not checked590006/01/2024COMPENSATION

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Nothing to ReportCheckbox checked

    144: Remarks and Signature

    Remarks
    Date of Notice
    06/05/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Michael Glen Kauffman

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ACET alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACET

    DatePrice TargetRatingAnalyst
    9/30/2024$7.00Buy
    Guggenheim
    9/11/2024Buy → Neutral
    H.C. Wainwright
    6/27/2023Buy → Neutral
    Guggenheim
    6/27/2023Mkt Outperform → Mkt Perform
    JMP Securities
    6/1/2023$20.00 → $6.00Overweight → Neutral
    JP Morgan
    9/21/2022$23.00Overweight
    JP Morgan
    3/31/2022$28.00Outperform
    SMBC Nikko
    3/8/2022$30.00Buy
    Truist Securities
    More analyst ratings

    $ACET
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Scientific Officer Aftab Blake covered exercise/tax liability with 535 shares, decreasing direct ownership by 15% to 2,981 units (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    1/27/26 4:46:53 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Technology Officer Healey Don covered exercise/tax liability with 535 shares, decreasing direct ownership by 13% to 3,452 units (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    1/27/26 4:46:12 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Schor Chen covered exercise/tax liability with 1,755 shares, decreasing direct ownership by 20% to 6,820 units (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    1/27/26 4:45:07 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Orbimed Advisors Llc bought $5,000,000 worth of shares (5,000,000 units at $1.00) (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    10/10/25 8:06:01 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Orbimed Advisors Llc bought $7,500,000 worth of shares (3,125,000 units at $2.40) (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    1/26/24 7:14:22 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gordon Carl L bought $7,500,000 worth of shares (3,125,000 units at $2.40) (SEC Form 4)

    4 - Adicet Bio, Inc. (0001720580) (Issuer)

    1/26/24 7:13:05 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Adicet Bio Inc.

    SCHEDULE 13G - Adicet Bio, Inc. (0001720580) (Subject)

    1/29/26 11:18:25 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events

    8-K - Adicet Bio, Inc. (0001720580) (Filer)

    1/7/26 8:30:12 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events

    8-K - Adicet Bio, Inc. (0001720580) (Filer)

    12/29/25 8:30:25 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12, 2026 in New York. Details of the event are as follows: Date: Thursday, February 12, 2026 Time: 2:00p.m. ET The live audio webcast can be accessed on the Investors section of Adicet Bio's website at http://www.adicetbio.com. An archived replay will be available for 30 days following the presentation. About Adicet Bio, Inc. Adicet Bio, Inc. is

    1/30/26 7:00:00 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones

    Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients with prulacabtagene leucel (prula-cel, formerly ADI-001) in ongoing and future clinical studies All seven cohorts now actively enrolling in Phase 1 autoimmune clinical program as first anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) patient is dosed in study Next clinical update from Phase 1 study of prula-cel in autoimmune disease expected in 1H/2026; plan to provide additional clinical update from the study in 2H/2026 Exploring potential to reduce need for conditioning with ongoing Phase 1 trial in treatm

    1/7/26 7:00:00 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio Announces Reverse Stock Split

    Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that its board of directors has determined to effect a one-for-16 reverse stock split of Adicet's common stock, par value $0.0001 per share. The reverse stock split ratio approved by the board of directors is within the previously disclosed range of ratios for a reverse stock split authorized by the stockholders of the company at the 2025 Special Meeting of Stockholders of Adicet held on December 19, 2025. The reverse stock split will take effect at 12:01 a.m. Eastern Time on December 30, 2025, and Adi

    12/26/25 8:30:00 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim resumed coverage on Adicet Bio with a new price target

    Guggenheim resumed coverage of Adicet Bio with a rating of Buy and set a new price target of $7.00

    9/30/24 8:04:57 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Adicet Bio from Buy to Neutral

    9/11/24 7:31:19 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio downgraded by Guggenheim

    Guggenheim downgraded Adicet Bio from Buy to Neutral

    6/27/23 10:07:31 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    Leadership Updates

    Live Leadership Updates

    View All

    Adicet Bio Appoints Michael Grissinger to the Board of Directors

    --Mr. Grissinger brings more than four decades of leadership experience in pharmaceutical business development and strategic transactions-- Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Michael Grissinger to its Board of Directors. Mr. Grissinger brings more than four decades of experience in business development, strategy, and M&A leadership roles at global pharmaceutical companies. "We are honored to welcome Michael to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "His extensive

    4/17/25 7:00:00 AM ET
    $ACET
    $APRE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio Appoints Julie Maltzman, M.D. as Chief Medical Officer

    Dr. Maltzman Brings Oncology and Autoimmune Experience in All Stages of Drug Development, from Early-Stage Research to Successful Regulatory Approvals and Commercialization Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Julie Maltzman, M.D. as Chief Medical Officer, effective January 13, 2025. Dr. Maltzman will lead the Adicet clinical development strategy to advance Adicet's robust autoimmune and oncology pipeline. "We are incredibly pleased to welcome Julie to the Adicet team. Her vast experience in successfully leading the c

    12/18/24 7:00:00 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio Appoints Lloyd Klickstein, M.D., Ph.D. to the Board of Directors

    Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the appointment of Lloyd Klickstein, M.D., Ph.D. to its Board of Directors. "We are pleased to welcome Dr. Klickstein to our Board of Directors," said Chen Schor, President and Chief Executive Officer of Adicet Bio. "Dr. Klickstein's expertise in rheumatology and immunology, proven track record in drug development and his scientific knowledge of our gamma delta T cell platform as a former executive at Adicet will be very valuable as we progress our autoimmune programs across multiple indications. I loo

    8/19/24 7:00:00 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

    SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

    11/14/24 5:46:11 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

    SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

    11/14/24 4:05:07 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Adicet Bio Inc.

    SC 13G/A - Adicet Bio, Inc. (0001720580) (Subject)

    11/14/24 4:00:05 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ACET
    Financials

    Live finance-specific insights

    View All

    Adicet Bio Announces Positive Preliminary Data from ADI-001 Phase 1 Study in Patients with Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

    -Clinical data to date supports a potentially transformational approach to treating autoimmune diseases with an off-the-shelf, one-time therapy- -As of the August 31, 2025 data cut-off date, all seven evaluable LN and SLE patients experienced rapid and sustained reductions in the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2K) score and Physician's Global Assessment (PGA) highlighting ADI-001's potential for durable effect on a broad range of lupus symptoms- -As of the August 31, 2025 data cut-off date, all five LN patients experienced improved renal function, including three complete renal responses and Definition Of Remission In Systemic lupus erythematosus (DORIS) rem

    10/7/25 6:45:00 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Provides Corporate Update and Highlights Strategic Priorities for 2024

    Expanding clinical development of ADI-001 into autoimmune diseases following clearance of Investigational New Drug Application (IND); plan to initiate Phase 1 clinical study in 2Q 2024 Focusing enrollment on mantle cell lymphoma (MCL) in ongoing ADI-001 Phase 1 clinical trial given favorable complete response (CR) rate, durability, and safety ADI-001 clinical update expected 2H 2024 ADI-270 IND submission in renal cell carcinoma expected in 2Q 2024 Updated cash runway into 2H 2025 Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate upda

    1/4/24 7:00:00 AM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Adicet Bio to Host Conference Call to Provide Updates on its Clinical Pipeline and Corporate Outlook

    Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that the Company will host a conference call and webcast presentation on Thursday, January 4, 2024 at 8:00am ET to provide an update on its clinical pipeline and corporate outlook. Conference Call and Webcast Event The live webcast of the presentation can be accessed by registering under "Presentations & Events" in the investors section of the Company's website at https://www.adicetbio.com. Upon registration, all participants will receive a confirmation email with a unique passcode to provide access to the webcast event. To

    1/3/24 4:01:00 PM ET
    $ACET
    Biotechnology: Pharmaceutical Preparations
    Health Care